

Resource Summary Report

Generated by [dkNET](#) on Sep 9, 2026

pSLCAR-CD19-BBz

RRID:Addgene_135992

Type: Plasmid

Proper Citation

RRID:Addgene_135992

Plasmid Information

URL: <http://www.addgene.org/135992>

Proper Citation: RRID:Addgene_135992

Insert Name: FMC63-41BB-3z-P2A-EGFP

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:32083149](#)

Vector Backbone Description: Backbone Marker:Heavily modified from LentiCRISPR v1 backbone; Vector Backbone:pSL; Vector Types:Mammalian Expression, Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pSLCAR-CD19-BBz

Record Creation Time: 20220422T221750+0000

Record Last Update: 20260905T074814+0000

Ratings and Alerts

No rating or validation information has been found for pSLCAR-CD19-BBz.

No alerts have been found for pSLCAR-CD19-BBz.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hanna EA, et al. (2026) A 3D multi-compartment assembloid to study combined immune cell infiltration and cytotoxicity. *Cell reports methods*, 6(2), 101307.

Futai R, et al. (2026) Allogeneic iPSC-derived ??T cells demonstrate antitumor efficacy against patient-derived tissues. *Stem cell reports*, 103018.

Ibrahim KE, et al. (2026) In vivo CAR T cell generation using retargeted and functionalized lentiviral vectors with reduced immunogenicity. *Nature communications*, 17(1).

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. *Cancer immunology research*, 14(4), 640.

Yang C, et al. (2025) A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity. *Cell reports. Medicine*, 6(10), 102409.

Moreno Rueda LY, et al. (2025) Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets. *Cell reports. Medicine*, 6(2), 101925.

Pinto IS, et al. (2025) Polymer-Based DNA Delivery Nanoplatfoms for Chimeric Antigen Receptor T Cells Engineering. *Biomacromolecules*, 26(6), 3628.

Liu G, et al. (2025) CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer. *bioRxiv : the preprint server for biology*.

Liao X, et al. (2024) The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. *Nature communications*, 15(1), 603.

Johnston AC, et al. (2024) Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors. *bioRxiv : the preprint server for biology*.

Hayashi H, et al. (2024) Development of a highly sensitive platform for protein-protein interaction detection and regulation of T cell function. *Proceedings of the National Academy of Sciences of the United States of America*, 121(33), e2318190121.

Crawford AJ, et al. (2024) Combined assembloid modeling and 3D whole-organ mapping captures the microanatomy and function of the human fallopian tube. *Science advances*, 10(39), eadp6285.

Ren J, et al. (2024) Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-V?2+ T cell malignancy. *Nature communications*, 15(1), 519.

Qiu F, et al. (2024) Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. *Nature communications*, 15(1), 4327.

McComb S, et al. (2024) Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22. *Molecular therapy*.

Oncology, 32(1), 200775.

Lu Q, et al. (2024) BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. Journal of nanobiotechnology, 22(1), 279.